DOCSLIB.ORG

2018 IID Meeting, Orlando, Florida

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

May 16-19, 2018 MEETING PROGRAM Rosen Shingle Creek Resort Orlando, Florida www.IID2018.org IID 2018 MEETING IID 2018 Program Chairs and Final Reviewers ESDR - Program Chairs JSID - Program Chairs SID - Program Chairs Michel Gilliet, MD Manabu Fujimoto, MD Nicole Ward, PhD Matthias Schmuth, MD Manabu Ohyama, MD/PhD Victoria Werth, MD ESDR – Final Reviewers JSID – Final Reviewers SID – Final Reviewers Hervé Bachelez, MD/PhD Riichiro Abe, MD/PhD Vladimir Botchkarev, MD/PhD Leopold Eckhart, PhD Manabu Fujimoto, MD Spiro Getsios, PhD Menno de Rie, MD/PhD Minoru Hasegawa, MD Daniel Kaplan, MD/PhD Bernhard Homey, MD Hironobu Ihn, MD/PhD Ethan Lerner, MD/PhD David Kelsell, PhD Kenji Kabashima, MD/PhD Lloyd Miller, MD/PhD Lionel Larue, PhD Takuro Kanekura, MD/PhD Peggy Myung, MD/PhD Caterina Missero, PhD Norito Katoh, PhD Marjana Tomic-Canic, PhD Edel O’Toole, PhD Tatsuyoshi Kawamura, MD/PhD Kevin Wang, MD/PhD Ralf Paus, MD/PhD Akiharu Kubo, MD/PhD Nicole Ward, PhD Sirkku Peltonen, MD/PhD Akimichi Morita, MD/PhD Victoria Werth, MD Neil Rajan, MD/PhD Manabu Ohyama, MD/PhD Martin Steinhoff, MD/PhD Ryuhei Okuyama, MD/PhD Marta Szell, DSc Tamio Suzuki, MD/PhD Thomas Werfel, MD Katsuto Tamai, MD/PhD Peter Wolf, MD Akemi Yamamoto, MD/PhD European Society for Japanese Society for Society for Investigative Dermatological Research Investigative Dermatology Dermatology Rue Cingria 7, Geneva 5F, 4-1-4 Hongo, Bunkyo-ku, Tokyo 526 Superior Avenue East, Suite 340 Switzerland, 1205 113-0033, Japan Cleveland, Ohio 44114, USA Tel: +41 22 321 48 90 Tel: +81-3-3830-0068 Tel: +01 216-579-9300 Email: [email protected] Email: [email protected] Email: [email protected] Web: www.esdr.org Web: www.jsid.org Web: www.sidnet.org ACKNOWLEDGEMENTS The organizers of IID 2018 gratefully acknowledge the many exhibitors and sponsors whose attendance has helped make this meeting possible. 2 IID 2018 MEETING WELCOME Michel Gilliet, MD Akimichi Morita, MD/PhD Russell P. Hall, MD ESDR President JSID President SID President As President of the ESDR, I would like to Every five (5) years, members of all the On behalf of the Society for Investigative cordially welcome you to Orlando for IID investigative dermatology and cutaneous Dermatology (SID), our colleagues at the 2018. The three (3) sister societies SID, biology societies throughout the world European Society for Dermatologic JSID and ESDR have organized a terrific gather together to exchange information Research (ESDR) and the Japanese program full of excellent skin science from and facilitate collaboration. The Society for Investigative Dermatology throughout the world. We have selected combination of high-quality science, (JSID), we are pleased that you’re able the top ranked abstracts for oral outstanding interactions with international to attend the 7th and final International presentation from over 1500 submissions colleagues, and the enjoyable city of Investigative Dermatology (IID) Meeting and invited exceptional international Orlando will make this a valuable and in Orlando. The IID Meeting is a unique scientists as guest lecturers. Besides great unforgettable experience. As neither of opportunity, occurring only once every science, the meeting will also provide a the three (3) sister societies, the European five (5) years bringing together basic, unique setting for social interactions with Society for Dermatological Research translational and clinical scientists… all international friends and colleagues during (ESDR), the Society for Investigative focused on advancing our understanding our Welcome Reception or social gathering. Dermatology (SID), and the Japanese of skin biology and disease. Scientists I look forward to seeing you at the Society for Investigative Dermatology from across the globe will gather to Rosen Shingle Creek Resort, in what (JSID), will have a meeting of their own discuss the latest in cutting edge science. promises to be an unforgettable event! in 2018, the International Investigative Our venue here at Rosen Shingle Dermatology (IID) Meeting will definitely Creek will bring us all together at one be the hot-spot of dermatologic and beautiful site; facilitating scientific cutaneous science in 2018! This will be interactions and collaboration. As always, the final IID Meeting with the current highlights of the meeting include the format. On May 9, 2013 during IID 2013, numerous opportunities for international representatives of the SID, ESDR, and JSID camaraderie; from the Welcome Reception signed a memorandum of understanding to the MUCH anticipated Social Event at to form a new organization, International Harry Potter™, to the Young Investigator Societies for Investigative Dermatology Pool Party, to the Closing Ceremonies (ISID) in Edinburgh, Scotland. The mission (where the city and venue for the new of the ISID is to unite all international International Society for Investigative organizations of scientists dedicated to Dermatology (ISID) 2023 Meeting will be investigative dermatology and cutaneous announced). I welcome you to IID 2018 biology with the purpose of encouraging and and hope that you enjoy the excellent facilitating international collaborations. science, reconnecting with long time The first ISID International Meeting will be colleagues and meeting many new friends held in "Asia/Oceania" in 2023. Therefore, from all over the world. the success of IID 2018 is important and definitely leads to ISID transition and future breakthroughs in investigative dermatology and cutaneous biology. I hope to see many of you at this special event this week in Orlando! 3 IID 2018 MEETING Meeting-At-A-Glance ————————————————————————————————————————————————— Wednesday, May 16, 2018 Aclaris Therapeutics Symposium 12:00 pm – 1:30 pm ————————————————————————————————————————————————— JAK ‘Be Nimble’: New Applications of Gatlin D-E 7:00 am – 2:00 pm International Trainee Retreat Program JAK Inhibitors in Dermatology By Invitation Only Conway ————————————————————————————————————————————————— ————————————————————————————————————————————————— Selected ePoster Discussions I 12:15 pm – 1:15 pm 8:00 am - 7:00 pm Registration • Carcinogenesis and Cancer Gatlin Foyer Kiosk #1 Gatlin Foyer Registration Counter ————————————————————————————————————————————————— Genetics Academic Industry Partnership Project 12:00 pm – 4:00 pm • Clinical Research: Epidemiology Gatlin Foyer Kiosk #2 (AIPP) Panzacola G-1 of Skin Diseases ————————————————————————————————————————————————— • Epithelial Biology Gatlin Foyer Kiosk #3 Future Leaders Symposium 2:00 pm – 4:00 pm • Innate Immunity, Microbiology, Gatlin Foyer Kiosk #4 Gatlin D-E Inflammation ————————————————————————————————————————————————— • Skin of Color Gatlin Foyer Kiosk #5 LEO Foundation Awards 4:00 pm – 5:00 pm • Tissue Regeneration and Gatlin Foyer Kiosk #6 Gatlin D-E Wound Healing ————————————————————————————————————————————————— Sponsored by: Rodan & Fields Opening Ceremonies 5:00 pm – 5:30 pm ————————————————————————————————————————————————— Gatlin D-E ESDR Rudi Cormane Lecture 2:00 pm – 2:30 pm ————————————————————————————————————————————————— Above and Beyond: New Frontiers in Gatlin D-E SID Rising Star Lecture 5:30 pm – 5:50 pm Cutaneous Immunology Sexual Dimorphism in Autoimmunity Gatlin D-E Tilo Biedermann, MD Johann Gudjonsson, MD/PhD ————————————————————————————————————————————————— ————————————————————————————————————————————————— JSID Tanioku Kihei Memorial Lecture 2:30 pm – 3:00 pm JSID Rising Star Lecture 5:50 pm – 6:10 pm Environment and Skin Gatlin D-E Skin Research Provides a Window into New Gatlin D-E Jean Krutmann, MD Aspects of Systemic Disease Pathogenesis ————————————————————————————————————————————————— Yoshihide Asano, MD/PhD Concurrent Mini-Symposia 3:15 pm – 5:45 pm ————————————————————————————————————————————————— 1. Carcinogenesis and Cancer Genetics Panzacola F-3/4 ESDR Rising Star Lecture 6:10 pm – 6:30 pm 2. Clinical Research: Epidemiology of Panzacola F-1/2 The Aged Skin Microenvironment Gatlin D-E Skin Diseases Amaya Viros, MD/PhD 3. Innate Immunity, Microbiology, Inflammation Gatlin D-E ————————————————————————————————————————————————— 4. Skin of Color Conway Welcome Reception 6:30 pm – 9:30 pm 5. Tissue Regeneration and Wound Healing Panzacola G-1 Terrace 6. Interdisciplinary Spotlight: Autophagy/Aging Panzacola G-2 ————————————————————————————————————————————————— ————————————————————————————————————————————————— Imaging In Cutaneous Biology Workshop 6:00 pm – 7:30 pm Panzacola G-2 Thursday, May 17, 2018 ————————————————————————————————————————————————— ————————————————————————————————————————————————— Sanofi Genzyme and Regeneron 6:00 pm – 7:30 pm Lilly Symposium 7:00 am – 8:30 am Pharmaceuticals Symposium Panzacola F-3/4 Taltz: Perspectives from Dual Specialties Gatlin D-E New Frontiers and Pivotal Investigation- Alice Bendix Gottlieb, MD/PhD Based Advances in the Pathoimmunobiology ————————————————————————————————————————————————— and Management of Atopic Dermatitis Promoting Diversity & Inclusion: 7:00 am – 8:30 am ————————————————————————————————————————————————— A Conversation for Trainees Panzacola G-1 Social Event 8:30 pm – 11:30 pm and Leadership The Wizarding World of Harry Potter™ ————————————————————————————————————————————————— at Universal Orlando Resort ™ Registration 8:00 am - 4:30 pm Ticketed Event: Gatlin Foyer Registration Counter ————————————————————————————————————————————————— Pre-Registration Required Plenary Session I 8:45 am – 9:45 am All attendees are to pick up their admission bracelets at the Gatlin
Recommended publications
  • Case Study of Nestlé1

    Case Study of Nestlé1

    CASE STUDY OF NESTLÉ1 INDEX PART A 1. Introduction 3 2. History 3 3. Industry Analysis and Competitors 5 3.1 Challenges of the food and beverage industry 6 3.2 Sales evolution of the industry 6 3.3 Qualitative Analysis: SWOT industry 8 3.4 Main competitors 9 3.5 Market Share 9 4. Business Model 10 4.1 Mission 10 4.2 Distinctive Factors 10 4.3 Corporate Governance 11 4.4 Corporate Social Responsibility 11 4.5 Segmentation of products 13 5. Questions 13 6. Bibliography 13 7. Notes 14 1 Case written by Clara Aguilar, Cristina Hey, Laura Plaza and Sara Zayas and supervised by Oriol Amat, BSM Universitat Pompeu Fabra, 2018 8. Annex 14 8.1 Balance Sheet 14 8.2 Income Statement 17 8.3 Cash Flow Statement 18 8.4 Ratios 20 PART B 1. Answer to the Questions Raised 22 2 PART A 1. INTRODUCTION “Nestlé” is a Swiss multinational food and beverage company whose business started in 1866. It is one of the largest food companies in the world, with presence in 191 countries, and more than 2,000 brands. Some of these are globally iconic while others are just regional, presenting a great variety of products, such as tea, coffee, bottled water, medical and baby food, breakfast cereals, and lots more. It is a well-known company world-wide, specially because of Nestlé milk chocolate bar, which is one of the most famous products. The company focuses on the production and supply of great quality and healthy food products. Nestle has a huge portfolio and is seen as an enormous competitor across the food industries.
  • REPORTER No 6396 W E D N E S D Ay 23 S E P T E M B E R 2015 V O L C X Lv I N O 1

    REPORTER No 6396 W E D N E S D Ay 23 S E P T E M B E R 2015 V O L C X Lv I N O 1

    CAMBRIDGE UNIVERSITY REPORTER NO 6396 W ED N E S D AY 23 S EPTEMBER 2015 V OL CXLV I N O 1 CONTENTS Notices Notices by Faculty Boards, etc. Calendar 2 Natural Sciences Tripos, Part II (Biological Notice of a Discussion on Tuesday, 13 October and Biomedical Sciences), 2015–16 11 2015 2 Natural Sciences Tripos, Part III (Experimental Preacher at Mere’s Commemoration in 2016 2 and Theoretical Physics) and Master of Nomination of the Proctors and Deputy Advanced Studies in Physics, 2015–16 12 Proctors for 2015–16 2 Form and conduct of examinations, 2016 Annual Reports 2 Asian and Middle Eastern Studies Tripos, Examination results statistics 2 Part II, 2016: correction 13 Vacancies, appointments, etc. Obituaries Electors to the Professorship of Comparative Obituary Notices 14 Philology 3 Graces Electors to the Professorship of Immunology 3 Grace submitted to the Regent House on Electors to the Sir Patrick Sheehy 23 September 2015 14 Professorship of International Relations 3 Acta Electors to the Professorship of Medieval History 4 Approval of Grace submitted to the Regent Electors to the William Wyse Professorship of House on 29 July 2015 14 Social Anthropology 4 Vacancies in the University 4 End of the Official Part of the ‘Reporter’ Elections, appointments, reappointment, and College Notices grants of title 5 Elections 15 Awards, etc. Vacancies 16 Scholarships and Prizes, etc. awarded 7 Other Notices 17 Events, courses, etc. Notice by the University Bellringer 17 Announcement of lectures, seminars, etc. 8 External Notices Notices by the General Board University of Oxford 17 Regulations for the University Library 9 The Cambridge Humanities Research Grants Scheme 9 Regulations for examinations Classical Tripos, Part II 10 Modern and Medieval Languages Tripos, Part IB 10 Bachelor of Theology for Ministry 10 PLISUB HED BY AUTHORITY 2 CAMBRIDGE UNIVERSITY REPORTER 23 September 2015 NOTICES Calendar 1 October, Thursday.
  • Financial Statements 2018

    Financial Statements 2018

    Financial Statements 2018 Consolidated Financial Statements of the Nestlé Group 2018 152nd Financial Statements of Nestlé S.A. Consolidated Financial Statements of the Nestlé Group 2018 Consolidated Financial Statements of the Nestlé Group 2018 63 65 Principal exchange rates 160 Statutory Auditor’s Report – Report on the Audit of the 66 Consolidated income statement for Consolidated Financial Statements the year ended December 31, 2018 166 Financial information – 5 year review 67 Consolidated statement of comprehensive income for the year 168 Companies of the Nestlé Group, joint ended December 31, 2018 arrangements and associates 68 Consolidated balance sheet as at December 31, 2018 70 Consolidated cash fl ow statement for the year ended December 31, 2018 71 Consolidated statement of changes in equity for the year ended December 31, 2018 73 Notes 73 1. Accounting policies 77 2. Scope of consolidation, acquisitions and disposals of businesses, assets held for sale and acquisitions of non-controlling interests 83 3. Analyses by segment 93 4. Net other trading and operating income/ (expenses) 94 5. Net fi nancial income/(expense) 95 6. Inventories 7. Trade and other receivables/payables 97 8. Property, plant and equipment 101 9. Goodwill and intangible assets 107 10. Employee benefi ts 117 11. Provisions and contingencies 119 12. Financial instruments 134 13. Taxes 137 14. Associates and joint ventures 139 15. Earnings per share 140 16. Cash fl ow statement 143 17. Equity 148 18. Transactions with related parties 150 19. Guarantees 20. Effects
  • Corporate Governance Report 30 June 2008

    Corporate Governance Report 30 June 2008

    Corporate Governance Report 30 June 2008 Board of Directors Executive Board Contents Preliminary remarks 3 1. Board of Directors 4 1.1 Members of the Board of Directors 4 1.2. Professional background and other activities and functions 6 1.3 Cross-involvement 8 1.4 Internal organisational structure 9 2. Executive Board 12 2.1 Members of the Executive Board 12 2.2. Professional background and other activities and functions 14 General Organisation of Nestlé S.A. 15 Situation at 30 June 2008 © 2008, Nestlé S.A., Cham and Vevey (Switzerland) Concept: Nestlé S.A., Group Governance, Vevey (Switzerland) Design: Nestec Ltd., Corporate Identity and Design, Vevey (Switzerland) 2 Nestlé | Corporate Governance Report June 2008 Preliminary remarks Nestlé S.A. publishes a full Corporate Governance Report, including a separate Compensation Report, which forms an integral part of the annual Management Report. We therewith comply with the requirements of the SWX Swiss Exchange (SWX) and its Corporate Governance Directive. The present document is a partial update of the Nestlé Corporate Governance Report 2007, indicating changes occurred on the Board of Directors and the Executive Board up to 30 June 2008. The annual Management Report is available on-line as a PDF file at http://www.nestle.com in English, French and German. Copies can be ordered at: http://www.nestle.com/MediaCenter/Order. Contact for Media: Nestlé S.A. Corporate Media Relations Avenue Nestlé 55 CH - 1800 Vevey (Switzerland) tel. +41 (0)21 924 22 00 fax +41 (0)21 922 63 34 e-mail: [email protected] Contact for Investors: Nestlé S.A.
  • Nestlé's Winning Formula for Brand Management

    Nestlé's Winning Formula for Brand Management

    Feature By Véronique Musson Nestlé’s winning formula for brand management ‘Enormous’ hardly begins to describe the trademark that develop products worldwide and are managed from our portfolio of the world’s largest food and drink company headquarters in Vevey, Switzerland or St Louis in the United States,” he explains. So eight trademark advisers, also based in Vevey, advise one – and the workload involved in managing it. But when or more strategic business units on the protection of strategic it comes to finding the best solutions to protect these trademarks, designs and copyrights, while one adviser based in St very valuable assets, Nestlé has found that what works Louis advises the petcare strategic business unit on trademarks and best for it is looking for the answers in-house related issues, as the global petcare business has been managed from St Louis since the acquisition of Ralston Purina in 2001. In parallel, 16 regional IP advisers spread around the world advise the Nestlé Imagine that you start your day with a glass of VITTEL water operating companies (there were 487 production sites worldwide at followed by a cup of CARNATION Instant Breakfast drink. Mid- the end of 2005) on all aspects of intellectual property, including morning you have a cup of NESCAFÉ instant coffee and snack on a trademarks, with a particular focus on local marks. The trademark cheeky KIT KAT chocolate bar; lunch is a HERTA sausage with group also includes a dedicated lawyer in Vevey who manages the BUITONI pasta-and-sauce affair, finished off by a SKI yogurt.
  • Immune Homeostasis

    Immune Homeostasis

    IMMUNE HOMEOSTASIS FUNDED PROJECTS FROM THE INNOVATION WORKSHOP 18-20 JULY 2017 AIMS THE SANDPIT PROCESS CAN BE BROKEN DOWN The immune system continues to intrigue and test us: as we get closer to finding ways of harnessing or modulating immune responses, new and unexpected consequences and INTO SEVERAL STAGES: challenges present themselves, often testing even our most fundamental understanding. Cancer Research UK and Arthritis Research UK came together to engage the research community to tackle the specific challenge of understanding how the immune system regulates itself under normal physiological conditions (immune homeostasis), how it is • Defining the scope of the challenge dysregulated in different diseases and how we can stimulate the immune response to prevent • Sharing understanding of the challenge and expertise brought to the sandpit by or treat disease (immunotherapy). participants We brought together researchers and clinicians in the fields of inflammatory disease, cancer, • Evolving common languages and terminologies amongst people from a diverse theoretical physics, computational medicine and other areas, whose expertise could be applied range of backgrounds and disciplines to the key questions concerning immune homeostasis. This workshop encouraged participants from a diverse range of backgrounds to melt barriers, develop a common language to promote • Breaking down preconceptions of researchers and stakeholders collaboration, and suggest new ways to harness the immune system to treat disease. • Taking part in break-out sessions focussed on challenges, using creative thinking techniques Director • Capturing outputs in the form of highly innovative feasibility study proposals The role of the Director was to work with the facilitators to lead the event and guide the process • A funding decision on those proposals at the sandpit, using “real time” peer-review.
  • The Rise of Modern International Order

    The Rise of Modern International Order

    George Lawson The rise of modern international order Book section (Accepted refereed) Original citation: Originally published in: Baylis, John, Smithson, Steve and Owens, Patricia, (eds.) The Globalization of World Politics: An Introduction to International Relations. Oxford, UK : Oxford University Press, 2016 , pp. 37-51 © 2016 The Authors This version available at: http://eprints.lse.ac.uk/68644/ Available in LSE Research Online: December 2016 LSE has developed LSE Research Online so that users may access research output of the School. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LSE Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain. You may freely distribute the URL (http://eprints.lse.ac.uk) of the LSE Research Online website. This document is the author’s submitted version of the book section. There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it. CH 2-The Rise of Modern International Order Chapter 2 The Rise of Modern International Order GEORGE LAWSON <start feature> Framing Questions When did modern international order emerge? To what extent was the emergence of modern international order shaped by the experience of the West? Is history important to understanding contemporary world politics? <end feature> Reader’s guide This chapter explores the rise of modern international order.
  • Pnas11052ackreviewers 5098..5136

    Pnas11052ackreviewers 5098..5136

    Acknowledgment of Reviewers, 2013 The PNAS editors would like to thank all the individuals who dedicated their considerable time and expertise to the journal by serving as reviewers in 2013. Their generous contribution is deeply appreciated. A Harald Ade Takaaki Akaike Heather Allen Ariel Amir Scott Aaronson Karen Adelman Katerina Akassoglou Icarus Allen Ido Amit Stuart Aaronson Zach Adelman Arne Akbar John Allen Angelika Amon Adam Abate Pia Adelroth Erol Akcay Karen Allen Hubert Amrein Abul Abbas David Adelson Mark Akeson Lisa Allen Serge Amselem Tarek Abbas Alan Aderem Anna Akhmanova Nicola Allen Derk Amsen Jonathan Abbatt Neil Adger Shizuo Akira Paul Allen Esther Amstad Shahal Abbo Noam Adir Ramesh Akkina Philip Allen I. Jonathan Amster Patrick Abbot Jess Adkins Klaus Aktories Toby Allen Ronald Amundson Albert Abbott Elizabeth Adkins-Regan Muhammad Alam James Allison Katrin Amunts Geoff Abbott Roee Admon Eric Alani Mead Allison Myron Amusia Larry Abbott Walter Adriani Pietro Alano Isabel Allona Gynheung An Nicholas Abbott Ruedi Aebersold Cedric Alaux Robin Allshire Zhiqiang An Rasha Abdel Rahman Ueli Aebi Maher Alayyoubi Abigail Allwood Ranjit Anand Zalfa Abdel-Malek Martin Aeschlimann Richard Alba Julian Allwood Beau Ances Minori Abe Ruslan Afasizhev Salim Al-Babili Eric Alm David Andelman Kathryn Abel Markus Affolter Salvatore Albani Benjamin Alman John Anderies Asa Abeliovich Dritan Agalliu Silas Alben Steven Almo Gregor Anderluh John Aber David Agard Mark Alber Douglas Almond Bogi Andersen Geoff Abers Aneel Aggarwal Reka Albert Genevieve Almouzni George Andersen Rohan Abeyaratne Anurag Agrawal R. Craig Albertson Noga Alon Gregers Andersen Susan Abmayr Arun Agrawal Roy Alcalay Uri Alon Ken Andersen Ehab Abouheif Paul Agris Antonio Alcami Claudio Alonso Olaf Andersen Soman Abraham H.
  • 2020 Zlatareva Iva 1521303 E

    2020 Zlatareva Iva 1521303 E

    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Tissue-specific butyrophilin-like proteins are TCR selecting ligands distinct from antigens Zlatareva, Iva Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 10. Oct. 2021 Tissue-specific butyrophilin-like proteins are gdTCR selecting ligands distinct from antigens Iva Ivanova Zlatareva King’s College London PhD Supervisors: Professor Adrian C.
  • In the United States District Court for the District of Delaware

    In the United States District Court for the District of Delaware

    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE TRUINJECT CORP., ) ) Plaintiff, ) C.A. No. 19-00592-LPS-JLH ) v. ) ) GALDERMA, S.A., GALDERMA ) LABORATORIES, L.P., NESTLÉ SKIN ) Jury Trial Demanded HEALTH, INC., ) ) Defendants. ) ) CORRECTED SECOND AMENDED COMPLAINT I. EXECUTIVE SUMMARY A. GABRIELLE RIOS SEES A MARKET NEED FOR TRUINJECT 1. Ms. Gabrielle Rios (“Ms. Rios”), the CEO of Plaintiff Truinject Corporation (“Truinject”) in this matter, worked at LexisNexis after college as an account manager. As an account manager, she learned how to use LexisNexis and other search engines to research news stories, press releases and other information she needed for her business. After LexisNexis she worked at Allergan, where she marketed neurotoxins and dermal fillers to medical providers for therapeutic and cosmetic injections. Allergan’s popular Botox product was among the neurotoxins she marketed at Allergan. Botox accounts for roughly half (50%) of the neurotoxin market, and two other companies—Merz and Galderma—sell products that account for most of the rest. Botox and other neurotoxins and dermal fillers1 typically are injected with syringes into patients’ faces and/or other sensitive parts of the body. 1 Dermal fillers are substances that add volume under a patient’s skin; neurotoxins are substances that relax muscles to smooth the overlying skin. Defendant Galderma Labs sells such products Truinject Corp.'s Corrected SECOND AMENDED COMPLAINT - as a matter of right(613629.2).docx 2. While marketing neurotoxins and fillers at Allergan, Ms. Rios worked with doctors and other medical providers who lacked advanced training in using neurotoxins and fillers safely when performing injections.
  • Corporate Governance Board of Directors Executive Board June 2006 Contents

    Corporate Governance Board of Directors Executive Board June 2006 Contents

    Corporate Governance Board of Directors Executive Board June 2006 Contents Preliminary remarks 3 1. Board of Directors 4 1.1 Members of the Board of Directors 4 1.2 Other activities and functions 6 1.3 Cross-involvement 8 1.4 Elections and terms of office 8 1.5 Internal organisational structure 9 2. Executive Board 12 2.1 Members of the Executive Board 12 2.2 Other activities and functions 14 General Organisation of Nestlé S.A. 16 © 2006, Nestlé S.A., Cham and Vevey (Switzerland) Concept: Nestec Ltd., Corporate Identity and Design, Vevey (Switzerland) 2 Nestlé Corporate Governance Report June 2006 Preliminary remarks Nestlé S.A. publishes a full Corporate Governance Report, which forms an integral part of the annual Management Report. We therewith comply with the requirement of the SWX Swiss Exchange (SWX) and its Corporate Governance Directive, obliging issuers to make key information, with regard to corporate governance practices within their company, available to investors. The full Corporate Goverance Report follows the structure of the SWX Directive. Texts in italics indicate quotations from this Directive. The present document is a partial update of the Nestlé Corporate Governance Report 2005, indicating changes occured on the Board of Directors, the Committes of the Board of Directors and the Executive Board up to 1 June 2006. The annual Management Report is available on-line as a PDF file at www.ir.nestle.com in English, French and German. Copies can be ordered at: http://www.nestle.com/Media_Center/Order.aspx Contact for Media: Nestlé S.A. Corporate Communications Avenue Nestlé 55 CH - 1800 Vevey (Switzerland) tel.
  • Nestle 55 Vevey, Switzerland Tel: 41-21-924-21-11 Fax: 41-21-924-28-13

    Nestle 55 Vevey, Switzerland Tel: 41-21-924-21-11 Fax: 41-21-924-28-13

    P r o f il e e t profile a Coffee, Water and Ki bbl e: r A P r of ile of the F ood and Bever age Giant po r o Nestlé c p r o Oct ober 2005 f P r epar ed by Richard Gir ar d P olar is Institute R esear cher il e corporate Table of Contents Introduction .........................................................................................................1 Chapter One: Organizational Profile .................................................................3 1.1 Operations .....................................................................................................3 1.2 Brands............................................................................................................4 1.3 Executives .....................................................................................................6 1.4 Board of Directors.........................................................................................7 1.5 Public Relations ............................................................................................8 1.6 University Links ............................................................................................8 Chapter Two: Economic Profile .......................................................................11 2.1 Financial Data..............................................................................................11 2.2 Joint Ventures/Alliances.............................................................................11 2.3 Lawsuits.......................................................................................................12